Home World News Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to... World News Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 406 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Selinexor June 15, 2022 FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma November 4, 2022 Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed... May 11, 2022 Colon capsule endoscopy – reshaping bowel cancer diagnosis April 14, 2021 Load more HOT NEWS Making Important Decisions During Cancer: A Survivor’s Story For the RTOG 9408, and this randomized 1,979 patients so you... Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent... Though the Pandemic Has Slowed, Many Are Still Struggling to Put...
